Biogen

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1978-01-01

Employees: 7.5K

Market Cap: $29.6B

Website: https://www.biogen.com

Introduction: Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMAD...

Clinical Trials

A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus (LTE AMETHYST)

Phase 3

Conditions: Chronic Cutaneous Lupus Erythematosus
Subacute Cutaneous Lupus Erythematosus

Interventions: Drug: BIIB059 (litifilimab)

First Posted Date: 2023-09-21

Last Posted Date: 2024-12-16

Lead Sponsor: Biogen

Target Recruit Count: 322

Registration Number: NCT06044337

Locations: 🇰🇷
The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Korea, Republic of
🇩🇪
Universitaetsklinikum Carl Gustav Carus TU, Dresden, Sachsen, Germany
🇲🇽
Centro de investigacion medica y reumatologia, Guadalajara, Mexico

and more 37 locations

A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Natalizumab

First Posted Date: 2023-06-29

Last Posted Date: 2024-08-23

Lead Sponsor: Biogen

Target Recruit Count: 400

Registration Number: NCT05925049

Locations: 🇺🇸
Research Site, Cambridge, Massachusetts, United States

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis

Phase 2

Recruiting

Conditions: Relapsing Forms of Multiple Sclerosis

Interventions: Drug: BIIB091
Drug: DRF
Drug: Placebo

First Posted Date: 2023-04-04

Last Posted Date: 2024-12-06

Lead Sponsor: Biogen

Target Recruit Count: 275

Registration Number: NCT05798520

Locations: 🇺🇸
Vanderbilt MS Center, Nashville, Tennessee, United States
🇺🇸
HonorHealth Neurology, Scottsdale, Arizona, United States
🇺🇸
Alta Bates Summit Medical Center, Berkeley, California, United States

and more 74 locations

A Study of Spinraza (Nusinersen) Exposure in Pregnant Women With Spinal Muscular Atrophy (SMA) Within Existing SMA Registries

Recruiting

Conditions: Muscular Atrophy, Spinal

Interventions: Other: No Intervention

First Posted Date: 2023-03-29

Last Posted Date: 2024-01-18

Lead Sponsor: Biogen

Target Recruit Count: 20

Registration Number: NCT05789758

Locations: 🇺🇸
Research Site, Cambridge, Massachusetts, United States

A Study to Evaluate Long-Term Safety of Vumerity and Tecfidera in Participants With Multiple Sclerosis (MS)

Not yet recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Diroximel Fumarate
Drug: Dimethyl Fumarate
Drug: Disease-Modifying Therapies (DMTs)

First Posted Date: 2023-03-14

Last Posted Date: 2024-05-28

Lead Sponsor: Biogen

Target Recruit Count: 10500

Registration Number: NCT05767736

Locations: 🇺🇸
Research Site, Cambridge, Massachusetts, United States

A Study to Evaluate the Efficacy and Safety of BIIB131 for Participants With Ischemic Stroke Between 4.5 and 24 Hours After Last Known Well

Phase 2

Withdrawn

Conditions: Ischemic Stroke

Interventions: Drug: Placebo
Drug: BIIB131

First Posted Date: 2023-03-10

Last Posted Date: 2024-02-12

Lead Sponsor: Biogen

Registration Number: NCT05764122

A Study of End of Dose Phenomena in Subcutaneous Natalizumab Treated Multiple Sclerosis (MS) Participants

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Natalizumab

First Posted Date: 2023-01-27

Last Posted Date: 2024-06-14

Lead Sponsor: Biogen

Target Recruit Count: 34

Registration Number: NCT05701423

Locations: 🇩🇪
Klinik für Neurologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany

A Study to Assess Pregnancy Outcomes in Women Exposed to Diroximel Fumarate

Recruiting

Conditions: Multiple Sclerosis

Interventions: Biological: Alemtuzumab
Drug: Diroximel Fumarate
Drug: Fingolimod
Drug: Glatiramer acetate
Biological: Interferon beta
Biological: Natalizumab
Biological: Ocrelizumab
Biological: Ofatumumab
Drug: Ozanimod
Biological: Peginterferon beta-1a
Drug: Ponesimod
Drug: Siponimod

First Posted Date: 2023-01-18

Last Posted Date: 2023-10-13

Lead Sponsor: Biogen

Target Recruit Count: 1178

Registration Number: NCT05688436

Locations: 🇺🇸
OptumInsight, Eden Prairie, Minnesota, United States

A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China

Phase 4

Active, not recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Dimethyl fumarate

First Posted Date: 2022-12-20

Last Posted Date: 2024-04-30

Lead Sponsor: Biogen

Target Recruit Count: 60

Registration Number: NCT05658484

Locations: 🇨🇳
Renji Hospital, Shanghai Jiatong Uni. School of Medicine, Shanghai, China
🇨🇳
Xiangya Hospital Central South University, Changsha, China
🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, China

and more 13 locations

Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Avonex
Drug: Diroximel Fumarate
Drug: Dimethyl Fumarate
Biological: Tysabri

First Posted Date: 2022-12-20

Last Posted Date: 2024-06-24

Lead Sponsor: Biogen

Target Recruit Count: 908

Registration Number: NCT05658497

Locations: 🇨🇭
Inselspital, Bern, Switzerland
🇺🇸
IQVIA US Office, Durham, North Carolina, United States
🇮🇪
St Vincent's University Hospital, Dublin, Ireland

and more 2 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy